Market Cap 193.42M
Revenue (ttm) 49.22M
Net Income (ttm) -36.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.69%
Debt to Equity Ratio 0.76
Volume 44,000
Avg Vol 143,996
Day's Range N/A - N/A
Shares Out 55.58M
Stochastic %K 4%
Beta 3.10
Analysts Strong Sell
Price Target $6.80

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Address:
8, rue de la Croix Jarry, Paris, France
PirateKingsLuffy
PirateKingsLuffy Oct. 26 at 4:22 AM
$EEIQ this is gonna go to the moon don't be left behind. $CLLS $ZKIN $QLGN
0 · Reply
IsabelSims1079
IsabelSims1079 Oct. 20 at 4:28 PM
$CLLS engineering immune therapies; AITX engineering enterprise AI — profitability plus expanding SARA visibility highlight discipline.
0 · Reply
FelisaLow596
FelisaLow596 Oct. 20 at 4:24 PM
$CLLS engineering immune therapies; AITX engineering enterprise AI — profitability plus expanding SARA visibility highlight discipline.
0 · Reply
PaulLaurent
PaulLaurent Oct. 19 at 4:33 PM
🧭 Weekly Swing Recap — October 19, 2025 $EVAX – +102% from our entry zone — swing winner this week. Clean trend; trims into strength worked. $KOPN – +35% from our entry zone — exceeded the profit target. $GANX – Profit target hit but required fast execution; otherwise breakeven. $CHEK – +21% from our entry zone — profit zone reached. $CLLS – +37% from our entry zone — profit zone reached. Tone: Solid week for swings. Keep prioritizing VWAP or pivot reclaims, scale out into strength, and protect gains with tight risk if momentum cools.
1 · Reply
JLynneB51671
JLynneB51671 Oct. 19 at 3:53 PM
$PRQR $CLLS $RYOJ Hey Y'all- PSA- Jay truly is for real!!! Jay is remarkable. He's not looking for personal gain in the least! We in his group have benefited galaxies above and beyond. Not only from trade notifications, but detailed, personalized advice, knowledge, and support. We keep growing everyday! It's a community void of any ulterior motive other than helping and supporting each other to not only make bank, but to genuinely lift up others overall. The ONLY thing Jay requests for in return is to pay it forward, to any degree you can. Most importantly is to support his true life's mission; to give back to the cancer fighting community. So there it is. GLTA!!! 🙏💙🙏 *this is a "testimonial" given of my own accord, btw, as a member of his community.
1 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 2:02 PM
$CLLS https://anachart.com/wp-content/uploads/ana_temp/1760709735_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:22 PM
Barclays has updated their rating for Cellectis ( $CLLS ) to Overweight with a price target of 8.
0 · Reply
rlkloehn
rlkloehn Oct. 17 at 12:54 AM
$CLLS for those who missed today’s presentation.. https://youtu.be/bJggV3uLbXI?feature=shared
1 · Reply
TraderJay85
TraderJay85 Oct. 17 at 12:06 AM
PRE-MARKET MOVERS (PMM) Last PMM we had 6 wins, 2 small losses, and 4 broke even. $PRQR 2.97 stop $CLLS 4.54 stop $RYOJ 4.35 Stop Never hold under support. if it goes below then sell. Jump back in if it comes back to last support. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply
Wolfsschanze
Wolfsschanze Oct. 16 at 8:21 PM
$CLLS NEW YORK - Cellectis (Euronext Growth:ALCLS - NASDAQ: CLLS), ein Biotechnologieunternehmen mit einer Marktkapitalisierung von 347,58 Mio. USD, hat vielversprechende klinische Daten aus seiner Phase-1-Studie BALLI-01 zur Evaluierung von lasme-cel (UCART22) bei Patienten mit rezidivierter/refraktärer B-Zell-akuter lymphatischer Leukämie (r/r B-ALL) bekannt gegeben. Hier die Fakto: Die Daten zeigten eine Gesamtansprechrate von 68 % mit dem Herstellungsprozess 2 von lasme-cel (n=22). Diese stieg bei der für Phase 2 empfohlenen Dosis auf 83 % (n=12) und erreichte in der Zielpopulation der Phase 2 sogar 100 % (n=9). Zulassung der FDA beschleunigt ... Gewinner Kaujen das jetzt . bzw.. stocken aufiiii Woll. God Luck !
0 · Reply
Latest News on CLLS
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 11:50 AM EDT - 2 months ago

Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript


Cellectis Reports Financial Results for the First Quarter 2025

May 12, 2025, 4:30 PM EDT - 5 months ago

Cellectis Reports Financial Results for the First Quarter 2025


Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 10:36 AM EDT - 8 months ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript


Cellectis: Poised To Start Answering Questions In 2025

Dec 12, 2024, 3:08 PM EST - 11 months ago

Cellectis: Poised To Start Answering Questions In 2025


Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:59 PM EST - 1 year ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript


Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript


Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024


Cellectis' Shareholders Meeting to be Held on December 22, 2023

Nov 17, 2023, 4:30 PM EST - 2 years ago

Cellectis' Shareholders Meeting to be Held on December 22, 2023


PirateKingsLuffy
PirateKingsLuffy Oct. 26 at 4:22 AM
$EEIQ this is gonna go to the moon don't be left behind. $CLLS $ZKIN $QLGN
0 · Reply
IsabelSims1079
IsabelSims1079 Oct. 20 at 4:28 PM
$CLLS engineering immune therapies; AITX engineering enterprise AI — profitability plus expanding SARA visibility highlight discipline.
0 · Reply
FelisaLow596
FelisaLow596 Oct. 20 at 4:24 PM
$CLLS engineering immune therapies; AITX engineering enterprise AI — profitability plus expanding SARA visibility highlight discipline.
0 · Reply
PaulLaurent
PaulLaurent Oct. 19 at 4:33 PM
🧭 Weekly Swing Recap — October 19, 2025 $EVAX – +102% from our entry zone — swing winner this week. Clean trend; trims into strength worked. $KOPN – +35% from our entry zone — exceeded the profit target. $GANX – Profit target hit but required fast execution; otherwise breakeven. $CHEK – +21% from our entry zone — profit zone reached. $CLLS – +37% from our entry zone — profit zone reached. Tone: Solid week for swings. Keep prioritizing VWAP or pivot reclaims, scale out into strength, and protect gains with tight risk if momentum cools.
1 · Reply
JLynneB51671
JLynneB51671 Oct. 19 at 3:53 PM
$PRQR $CLLS $RYOJ Hey Y'all- PSA- Jay truly is for real!!! Jay is remarkable. He's not looking for personal gain in the least! We in his group have benefited galaxies above and beyond. Not only from trade notifications, but detailed, personalized advice, knowledge, and support. We keep growing everyday! It's a community void of any ulterior motive other than helping and supporting each other to not only make bank, but to genuinely lift up others overall. The ONLY thing Jay requests for in return is to pay it forward, to any degree you can. Most importantly is to support his true life's mission; to give back to the cancer fighting community. So there it is. GLTA!!! 🙏💙🙏 *this is a "testimonial" given of my own accord, btw, as a member of his community.
1 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 2:02 PM
$CLLS https://anachart.com/wp-content/uploads/ana_temp/1760709735_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:22 PM
Barclays has updated their rating for Cellectis ( $CLLS ) to Overweight with a price target of 8.
0 · Reply
rlkloehn
rlkloehn Oct. 17 at 12:54 AM
$CLLS for those who missed today’s presentation.. https://youtu.be/bJggV3uLbXI?feature=shared
1 · Reply
TraderJay85
TraderJay85 Oct. 17 at 12:06 AM
PRE-MARKET MOVERS (PMM) Last PMM we had 6 wins, 2 small losses, and 4 broke even. $PRQR 2.97 stop $CLLS 4.54 stop $RYOJ 4.35 Stop Never hold under support. if it goes below then sell. Jump back in if it comes back to last support. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
0 · Reply
Wolfsschanze
Wolfsschanze Oct. 16 at 8:21 PM
$CLLS NEW YORK - Cellectis (Euronext Growth:ALCLS - NASDAQ: CLLS), ein Biotechnologieunternehmen mit einer Marktkapitalisierung von 347,58 Mio. USD, hat vielversprechende klinische Daten aus seiner Phase-1-Studie BALLI-01 zur Evaluierung von lasme-cel (UCART22) bei Patienten mit rezidivierter/refraktärer B-Zell-akuter lymphatischer Leukämie (r/r B-ALL) bekannt gegeben. Hier die Fakto: Die Daten zeigten eine Gesamtansprechrate von 68 % mit dem Herstellungsprozess 2 von lasme-cel (n=22). Diese stieg bei der für Phase 2 empfohlenen Dosis auf 83 % (n=12) und erreichte in der Zielpopulation der Phase 2 sogar 100 % (n=9). Zulassung der FDA beschleunigt ... Gewinner Kaujen das jetzt . bzw.. stocken aufiiii Woll. God Luck !
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 16 at 4:17 PM
$CLLS has reversed -7% lower to 0% (~1Mv) a moment ago, 10/17 options, follow for more volatility.
0 · Reply
rlkloehn
rlkloehn Oct. 16 at 3:33 PM
$CLLS https://www.cellectis.com/uploads/files/Cellectis_RD_Day_Full_Deck..pdf
0 · Reply
Toptradersam
Toptradersam Oct. 16 at 2:53 PM
$PRAX $MIRA $LGCB $CLLS Pattern breakdown + trade plan here 📢 https://www.youtube.com/watch?v=Ncy2brMByqM
0 · Reply
UnicornPicks
UnicornPicks Oct. 16 at 1:51 PM
0 · Reply
biotech
biotech Oct. 16 at 1:47 PM
its getting clownesque $CLLS marketcap $350M $SGMO $200M
1 · Reply
Stock_Catcher
Stock_Catcher Oct. 16 at 1:34 PM
$CLLS thin
0 · Reply
BigSqueezeComing
BigSqueezeComing Oct. 16 at 1:09 PM
$CLLS Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers By Cellectis Inc. | October 16, 2025, 7:00 AM
0 · Reply
topstockalerts
topstockalerts Oct. 16 at 1:02 PM
Pre Market Top Gainers PT2 $MIRA $SOND $ADAP $AUUD $CLLS
0 · Reply
YeseniamoHousego
YeseniamoHousego Oct. 16 at 12:52 PM
CVKD Exciting news: Cadrenal Therapeutics Company Webcast @ Lytham Partners Fall 2025 Investor Conference. Watch live here: https://youtu.be/NfPbBjgeIbg?si=2xPvJ2_YJQjHipGa $UROY $URCCF $CLLS $AUUD $GRAL
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 16 at 12:43 PM
$CLLS (+20.0% pre) Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers https://ooc.bz/l/80758
0 · Reply
mikefbi
mikefbi Oct. 16 at 12:31 PM
$CLLS Patience
0 · Reply
rlkloehn
rlkloehn Oct. 16 at 11:22 AM
$CLLS Details of the Event: Date: Today, October 16, 2025 Time: 08:30 – 10:30 a.m. ET Format: In-person and live webcast Webcast: Join live via https://us06web.zoom.us/j/8463084840
0 · Reply